[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Cullinan Therapeutics Inc (CGEM)

Cullinan Therapeutics Inc (CGEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,325,070
  • Shares Outstanding, K 64,355
  • Annual Sales, $ 0 K
  • Annual Income, $ -219,880 K
  • EBIT $ -222 M
  • EBITDA $ -222 M
  • 60-Month Beta 0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 3.75

Options Overview Details

View History
  • Implied Volatility 110.36% (-2.57%)
  • Historical Volatility 52.98%
  • IV Percentile 12%
  • IV Rank 7.46%
  • IV High 740.76% on 09/19/25
  • IV Low 59.52% on 08/18/25
  • Expected Move (DTE 3) 0.00 (0.00%)
  • Put/Call Vol Ratio 1.21
  • Today's Volume 197
  • Volume Avg (30-Day) 332
  • Put/Call OI Ratio 1.04
  • Today's Open Interest 6,051
  • Open Int (30-Day) 4,665
  • Expected Range 20.59 to 20.59

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $-0.78
  • Number of Estimates 6
  • High Estimate $-0.71
  • Low Estimate $-0.90
  • Prior Year $-0.77
  • Growth Rate Est. (year over year) -1.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.02 +28.59%
on 08/03/26
21.22 -2.92%
on 08/17/26
+2.91 (+16.45%)
since 07/17/26
3-Month
11.68 +76.45%
on 06/10/26
21.22 -2.92%
on 08/17/26
+5.73 (+38.53%)
since 05/18/26
52-Week
5.68 +262.68%
on 10/03/25
21.22 -2.92%
on 08/17/26
+12.65 (+159.12%)
since 08/18/25

Most Recent Stories

More News
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the REZILIENT3 trial, a global Phase 3 clinical trial evaluating...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics: Q2 Earnings Snapshot

Cullinan Therapeutics: Q2 Earnings Snapshot

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

CLN-978 (CD19 TCE) multi-dose regimen data in RA in Q3 2026 and SLE in Q4 2026; Phase 2 expansion studies to begin early 2027 Velinotamig (BCMA TCE) multi-dose regimen data in SLE in Q4 2026; Phase...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics Reports Tomorrow But Analysts Haven't Lowered Their Targets

Barchart Research What to Expect from CGEM Earnings CGEM Generated August 5, 2026 Current Price $17.61 EPS Estimate $$-0.71 Consensus Rating Strong Buy Average Move 3.12% Cullinan Therapeutics Reports...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics Announces Positive End-of-Phase 1 Meeting with FDA for CLN-049 and Advances Program to a Potentially Registrational Phase 2 Study in AML

CAMBRIDGE, Mass., July 28, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class,...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics Shares New Clinical Data Across Its Portfolio of T Cell Engager Programs Targeting CD19 and BCMA in Autoimmune Diseases

CLN-978 (CD19 TCE) EULAR data demonstrated potential for immune reset, including remissions, in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) CLN-978 data from the first RA...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics Presents Initial Clinical Data for CLN-978, a CD19xCD3 T Cell Engager, at the EULAR 2026 Congress

Clinical benefit, including remissions, demonstrated in both systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients following a single target dose of CLN-978  Deep, dose-dependent...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics to Host Immunology Day to Showcase Promising Initial Clinical Data in Autoimmune Diseases for CLN-978, a CD19 T Cell Engager, and Velinotamig, a BCMA T Cell Engager

New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) studies  Initial data from the first multi-dose cohort...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Orphan Drug Designation underscores the potential of CLN-049, a novel FLT3xCD3 T cell engager, to address significant unmet need in AML CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Cullinan...

CGEM : 20.60 (+0.05%)
Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress

CAMBRIDGE, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc.  (Nasdaq: CGEM), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact...

CGEM : 20.60 (+0.05%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Cullinan Therapeutics Inc. is a biopharmaceutical company focused on developing modality-agnostic targeted therapies. The company's product pipeline consists CLN-978. Cullinan Therapeutics Inc., formerly known as Cullinan Oncology Inc., is based in CAMBRIDGE, Mass.

See More

Key Turning Points

3rd Resistance Point 22.56
2nd Resistance Point 21.89
1st Resistance Point 21.24
Last Price 20.60
1st Support Level 19.92
2nd Support Level 19.25
3rd Support Level 18.60

See More

52-Week High 21.22
Last Price 20.60
Fibonacci 61.8% 15.28
Fibonacci 50% 13.45
Fibonacci 38.2% 11.62
52-Week Low 5.68

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.